866-997-4948(US-Canada Toll Free)

Influenza Partnering 2010-2015

Published By :

Current Partnering

Published Date : May 2015

Category :

Therapeutic Area

No. of Pages : 100 Pages

The Influenza Partnering 2010-2015 report provides understanding and access to the influenza partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in influenza partnering deals
Top influenza deals by value
Deals listed by company A-Z, industry sector, stage of development, technology type

The Influenza Partnering 2010-2015 provides understanding and access to the influenza partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an analysis of influenza partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors influenza technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This data driven report contains over 150 links to online copies of actual influenza deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of influenza partnering trends.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in partnering since 2010, including a summary of deals by industry sector, stage of development, deal type, and technology type.

Chapter 3 provides an overview of the average deal terms since 2010. The chapter includes deals with a stage of development announced by headline value, upfront value, milestone value and royalty rate. Numerous tables outline financial trends.

Chapter 4 provides an overview of the most active dealmakers, top dealmakers by value, active big pharma and big biotech dealmakers including contract documents where available.

Chapter 5 provides a comprehensive directory of partnering deals signed and announced since 2010. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of influenza technologies and products.

Report scope

Influenza Partnering 2010-2015 is intended to provide the reader with an in-depth understanding and access to influenza trends and structure of deals entered into by leading companies worldwide.

This data driven report includes:

Trends in influenza dealmaking in the biopharma industry since 2010
Access to summary headline, upfront, milestone and royalty data
Access to over 150 influenza deals
The leading influenza deals by value since 2010

In Influenza Partnering 2010-2015, the available deals are listed by:

Headline value
Upfront payment value
Royalty rate value
Company A-Z
Industry sector
Stage of development at signing
Deal component type
Technology type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in influenza partnering
2.1. Introduction
2.2. Influenza partnering over the years
2.3. Influenza partnering by deal type
2.4. Influenza partnering industry sector
2.5. Influenza partnering by stage of development
2.6. Influenza partnering by technology type
Chapter 3 – Average deal terms for influenza
3.1 Introduction
3.2 Average deal terms for influenza
3.3 Influenza headline values with median calculation
3.4 Influenza upfront values with median calculation
3.5 Influenza milestone values with median calculation
3.6 Influenza royalty rates with median calculation
Chapter 4 – Active influenza dealmakers
4.1. Introduction
4.2 Most active influenza dealmakers
4.3. Top influenza deals by value
4.4 Big pharma deal activity
4.5 Big biotech deal activity
Chapter 5 – Influenza dealmaking directory
5.1. Introduction
5.2. Company A-Z
5.3. By deal type
5.4. By industry sector
5.5. By stage of development
5.6. By technology type
Chapter 6 – Partnering resource center
6.1. Online partnering
6.2. Partnering events
6.3. Further reading on dealmaking
Appendices
Appendix 1 – Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from Current Partnering
Order Form – Reports
Order Form – Subscription Access Products
Table of figures
Figure 1: Influenza partnering since 2010
Figure 2: Influenza dealmaking activity– 2010 to 2015
Figure 3: Influenza partnering by deal type since 2010
Figure 4: Influenza partnering by industry sector since 2010
Figure 5: Influenza partnering by stage of development since 2010
Figure 6: Influenza partnering by technology type since 2010
Figure 7: Influenza deals with a headline value
Figure 8: Influenza deals with upfront payment values
Figure 9: Influenza deals with milestone payments
Figure 10: Influenza deals with royalty rates, %
Figure 11: Top influenza deals by value since 2010
Figure 12: Big pharma – top 50 – influenza deals 2010 to 2015
Figure 13: Big pharma influenza deal frequency – 2010 to 2015
Figure 14: Big biotech – top 50 – influenza deals 2010 to 2015
Figure 15: Big biotech influenza deal frequency – 2010 to 2015
Figure 16: Online partnering resources
Figure 17: Forthcoming partnering events
Figure 18: Deal type definitions

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *